Feedback appointed to national NHS AI procurement framework
· The national framework addresses the Provision of Artificial Intelligence (A.I), Imaging and Radiotherapy Equipment, Associated Products and Diagnostic Imaging to public and private sector organisations
· Bleepa has been awarded onto the framework as a product which can facilitate the deployment of AI imaging tools into frontline clinical settings through mobile devices, enabling on-the-go access to AI
· The framework's estimated overall value of up to £360m enables any NHS body a route to procure the Bleepa AI solution for the purpose of developing, evaluating or clinically delivering AI imaging tools
London, 29 September 2021: Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist clinical communication company, announces that it has been awarded a place on a national procurement framework: The Provision Artificial Intelligence (A.I), Imaging and Radiotherapy Equipment, Associated Products and Diagnostic Imaging.
The Company has developed an AI module for the Bleepa communication platform that enables third party AI tools to be deployed within the app by frontline clinical users in order to assist with the diagnostic interpretation of medical imaging studies such as X-rays, CT scans and MRIs. The AI module has already been configured to deploy the AI tools of our commercial partners Qure.ai and Axial 3D.
The Bleepa AI module will allow NHS Bleepa customers to engage with AI tools of their choosing, knowing that they have a secure route of deployment right into the hands of their clinicians. Bleepa's availability as a mobile platform allows these AI tools to be deployed in any connected setting realising the full benefits of AI driven point-of-care diagnostics in more places and in a way that can't be recognised through traditional PACS based deployment, that is largely confined to desktop PCs within hospitals.
Enabling on-the-go access to the latest AI diagnostic support tools is the next evolution in the Company's mission to enable clinicians to make better decisions faster from any location. The framework will allow NHS organisations to buy the Bleepa AI solution as a platform for AI tool deployment, allowing them to meaningfully engage with any number of AI tools knowing that there is one common route for deployment into their clinical setting. The Company will additionally charge the AI companies a deployment fee through the platform.
The framework is run by Shared Business Services (SBS) on behalf of NHS organisations and enables NHS customers to directly procure equipment related to AI imaging, including Bleepa's AI module. The framework has an estimated overall value of up to £360m which lasts until 02/05/2025 and will be a key resource to enable the NHS to engage with AI technology. Details of the framework can be found at:
SBS describe the framework: "This is a framework agreement for the supply of Artificial Intelligence software and platforms and also for the supply of Medical Imaging and Radiotherapy equipment, associated products and Diagnostic Imaging equipment. The framework aims to provide a simple, effective, efficient and compliant route to market for the purchase/supply of a broad range of medical imaging and radiology products and services, including related artificial intelligence solutions. This will be for use by both NHS Customers (and other public & private sector organisations) through means of either direct call-off or further competition if required."
Dr Tom Oakley, CEO of Feedback, said: "This national framework is recognition of the increasing interest in AI technology across the NHS and will enable NHS customers to directly procure the Bleepa AI module as a vehicle for delivering the ever-growing array of AI imaging tools available. Clinicians do not want multiple apps on their devices and there is a clear role for a single platform that facilitates the deployment of multiple AI tools. As a mobile first solution, that additionally facilitates patient pathways and clinical case discussion, Bleepa is the perfect deployment platform for AI tools, we can put the latest AI technology literally into the hands of clinicians, through their own devices, in any internet connected location, allowing truly on-the-go access to the best available diagnostic support tools and point-of-care deployment of AI technology in even more care settings."
Tom Oakley, CEO
Lindsay Melvin, CFO
+44 (0)1954 718072
| || |
Panmure Gordon (UK) Limited (NOMAD and Broker)
Emma Earl/Freddy Crossley (Corporate Finance)
Rupert Dearden (Corporate Broking)
+44 (0)20 7886 2500
| || |
Walbrook PR Ltd
Tel: 020 7933 8780 or firstname.lastname@example.org
Paul McManus/Nick Rome/Nicholas Johnson
07980 541 893 or 07748 325 236 or 07884 664 686
Notes to Editors
Feedback plc (AIM: FDBK) is a pioneer of regulated clinical communication products. Its core product, Bleepa, is a revolutionary medical imaging communications app, providing an easy-to-use, high quality tool to enable remote and secure communications between front-line clinicians and teams. Importantly, it is the only CE marked medical imaging communications platform on the NHSx clinical communications tools framework. Bleepa has unparalleled functionality for everyday practice and can be accessed from any internet-connected device, enabling control of patient cases when on the go.
Its highly scalable Software as a Service ("SaaS") based revenue model will provide increasing levels of visibility as the Company grows its customer base. With a growing distribution base and technology in place, the focus is on leveraging key relationships in order to drive sales both in the UK and internationally to all forms of care providers. As a fully certified medical device, Bleepa aims to disrupt the medical imaging communications market and, importantly, increase the accuracy and speed of clinical review.
About NHS Shared Business Services
Established in 2005 by the Department of Health and Social Care (DHSC) in a partnership with digital experts Sopra Steria, its services are aimed at increasing efficiency and quality, saving time and money, and supporting patient care. The DHSC is transforming its current multiple delivery pathways into one intelligent, interconnected ecosystem that meets the ever-changing needs of the NHS in the digital world. Offering a seamless experience with a single sign-on, its modular solutions are aimed at enabling NHS organisations and suppliers to access the services they need, when they need them including access to suppliers or tendering for a multi-million pound project.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.